Molekulargenetische Diagnostik
Praxis Dr. Mato Nagel

Gliom-Neigung

Unter Gliom werden Tumoren des Zentralnervensystems zusammengefasst die von den Glia-Zellen ausgehen. Eine Neigung zu diesen Tumoren scheint bei somatischen Mutationen des IDH1-Gens zu bestehen.

Gliederung

Erbliche Nervenerkrankungen
Alzheimer Erkrankung
Arts-Syndrom
Autismus
Autosomal dominante zerebelläre Ataxie mit Schwerhörigkeit und Narkolepsie
Autosomal rezessive spastische Paraplegie 44
Brunner-Syndrom
Charcot-Marie-Tooth-Hoffmann-Krankheit
Erbliche Erkrankungen der Muskeln
Gliom-Neigung
IDH1
Hereditäre benigne Chorea
Hereditäre distale Motorneuronen-Neuropathie Typ 5A
Hereditäre sensorisch-autonome Neuropathie Typ 2A
Hereditäre sensorische Neuropathie Typ 1E
Hirnmalformation mit Urogenitaldefekten
Hypokalämische periodische Paralyse 1
Hypomyelinisierte Leukodystrophy 2
Idiopathische Kalzifikation der Basalganglien 1
Kongenitale Schmerzunempfindlichkeit mit Anhidrose
Migräne
Nemaline-Myopathy 5
Neonatale Enzephalopathie mit Mikrozephalie
Porenzephalie
Rett-Syndrom
Spastische Paraplegie 17 mit Amyotrophie der Hände und Füße
Syndrom der Intelligenzminderung mit stark verzögerter Sprachentwicklung und milden Dysmorphien
Vaskuläre Demenz
X-chromosomale syndromale mentale Retardierung 13
Zerebrale Mikroangiopathie mit Blutung

Referenzen:

1.

Piccirillo SG et. al. (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.

[^]
2.

Singh D et. al. (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma.

[^]
3.

Jones DT et. al. (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

[^]
4.

Parsons DW et. al. (2008) An integrated genomic analysis of human glioblastoma multiforme.

[^]
5.

Yan H et. al. (2009) IDH1 and IDH2 mutations in gliomas.

[^]
6.

Dubbink HJ et. al. (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

[^]
7.

Bralten LB et. al. (2011) IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.

[^]
8.

Flavahan WA et. al. (2016) Insulator dysfunction and oncogene activation in IDH mutant gliomas.

[^]
9.

None (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

[^]
10.

Thuwe I et. al. (1979) Familial brain tumour.

[^]
11.

de Tribolet N et. al. (1979) Familial gliomas.

[^]
12.

von Motz IP et. al. (1977) Astrocytoma in three sisters.

[^]
13.

Clarenbach P et. al. (1979) Simultaneous clinical manifestation of subependymoma of the fourth ventricle in identical twins. Case report.

[^]
14.

Ransom DT et. al. (1992) Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas.

[^]
15.

von Deimling A et. al. (1992) Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas.

[^]
16.

Wong AJ et. al. (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas.

[^]
17.

Olopade OI et. al. (1992) Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas.

[^]
18.

Sainati L et. al. (1992) Cytogenetic t(11;17)(q13;q21) in a pediatric ependymoma. Is 11q13 a recurring breakpoint in ependymomas?

[^]
19.

Griffin CA et. al. (1992) Chromosome abnormalities in low-grade central nervous system tumors.

[^]
20.

Bigner SH et. al. (1990) Cytogenetics and molecular genetics of malignant gliomas and medulloblastoma.

[^]
21.

Duhaime AC et. al. (1989) Simultaneous presentation of glioblastoma multiforme in siblings two and five years old: case report.

[^]
22.

Fujimoto M et. al. (1989) Loss of heterozygosity on chromosome 10 in human glioblastoma multiforme.

[^]
23.

Geraghty AV et. al. (1989) Prenatal diagnosis of fetal glioblastoma multiforme.

[^]
24.

el-Azouzi M et. al. (1989) Loss of distinct regions on the short arm of chromosome 17 associated with tumorigenesis of human astrocytomas.

[^]
25.

Chemke J et. al. (1985) Familial glioblastoma multiforme without neurofibromatosis.

[^]
26.

Heuch I et. al. (1986) Glioblastoma multiforme in three family members, including a case of true multicentricity.

[^]
27.

Honan WP et. al. (1987) Familial subependymomas.

[^]
28.

Bigner SH et. al. (1988) Specific chromosomal abnormalities in malignant human gliomas.

[^]
29.

Munoz DG et. al. (1988) Cerebral malignant tumors with ependymal and choroidal differentiation in two siblings.

[^]
30.

Vieregge P et. al. (1987) Familial glioma: occurrence within the "familial cancer syndrome" and systemic malformations.

[^]
31.

Leblanc R et. al. (1986) Familial mixed oligodendrocytic-astrocytic gliomas.

[^]
32.

Henn W et. al. (1986) Polysomy of chromosome 7 is correlated with overexpression of the erbB oncogene in human glioblastoma cell lines.

[^]
33.

Isamat F et. al. (1974) Genetic implications of familial brain tumors.

[^]
34.

Armstrong RM et. al. (1969) Familial gliomas.

[^]
35.

None (1971) Deaths from childhood leukemia and solid tumors among twins and other sibs in the United States, 1960-67.

[^]
36.

Downward J et. al. () Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.

[^]
37.

Schianchi P et. al. (1980) Familial brain tumors: rhombencephalon-astrocytoma grade I in father and son.

[^]
38.

Chen P et. al. (1995) Constitutional p53 mutations associated with brain tumors in young adults.

[^]
39.

Fults D et. al. (1993) Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme.

[^]
40.

Ryken TC et. al. (1994) Familial occurrence of subependymoma. Report of two cases.

[^]
41.

Kyritsis AP et. al. (1994) Germline p53 gene mutations in subsets of glioma patients.

[^]
42.

Karlbom AE et. al. (1993) Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10.

[^]
43.

Bögler O et. al. (1995) The p53 gene and its role in human brain tumors.

[^]
44.

von Deimling A et. al. (1995) Molecular pathways in the formation of gliomas.

[^]
45.

Kimmelman AC et. al. (1996) Loss of heterozygosity of chromosome 10p in human gliomas.

[^]
46.

Chattopadhyay P et. al. (1997) Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours.

[^]
47.

Mollenhauer J et. al. (1997) DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours.

[^]
48.

Chernova OB et. al. (1998) A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors.

[^]
49.

Simons A et. al. (1999) Isolation and characterization of glioblastoma-associated homozygously deleted DNA fragments from chromosomal region 9p21 suggests involvement of multiple tumour suppressor genes.

[^]
50.

Smith JS et. al. (2000) A transcript map of the chromosome 19q-arm glioma tumor suppressor region.

[^]
51.

Frederick L et. al. (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

[^]
52.

Ueki K et. al. (1997) ANOVA, a putative astrocytic RNA-binding protein gene that maps to chromosome 19q13.3.

[^]
53.

Tachibana I et. al. (2000) Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma.

[^]
54.

Holland EC et. al. (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.

[^]
55.

Reilly KM et. al. (2000) Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.

[^]
56.

Esteller M et. al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

[^]
57.

Malmer B et. al. (2001) Genetic epidemiology of glioma.

[^]
58.

de Andrade M et. al. (2001) Segregation analysis of cancer in families of glioma patients.

[^]
59.

Nishimoto A et. al. (2001) Functional evidence for a telomerase repressor gene on human chromosome 10p15.1.

[^]
60.

Marie Y et. al. (2001) OLIG2 as a specific marker of oligodendroglial tumour cells.

[^]
61.

Hoang-Xuan K et. al. (2001) Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.

[^]
62.

Jin W et. al. (2000) p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas.

[^]
63.

Pollack IF et. al. (2002) Expression of p53 and prognosis in children with malignant gliomas.

[^]
64.

Gutmann DH et. al. (2002) Mouse glioma gene expression profiling identifies novel human glioma-associated genes.

[^]
65.

Cartron PF et. al. (2002) The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival of glioblastoma multiforme patients.

[^]
66.

Staal FJ et. al. (2002) A novel germline mutation of PTEN associated with brain tumours of multiple lineages.

[^]
67.

Hu J et. al. (2002) High-resolution genome-wide allelotype analysis identifies loss of chromosome 14q as a recurrent genetic alteration in astrocytic tumours.

[^]
68.

Leuraud P et. al. (2003) Telomerase reactivation in malignant gliomas and loss of heterozygosity on 10p15.1.

[^]
69.

KJELLIN K et. al. (1960) The occurrence of brain tumors in several members of a family.

[^]
70.

PARKINSON D et. al. (1962) Oligodendrogliomas. Simultaneous appearance in frontal lobes of siblings.

[^]
71.

Yokota T et. al. (2003) A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor.

[^]
72.

Hegi ME et. al. (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

[^]
73.

Aldape KD et. al. (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.

[^]
74.

Reilly KM et. al. (2004) Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.

[^]
75.

Stupp R et. al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

[^]
76.

Hegi ME et. al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma.

[^]
77.

Liang Y et. al. (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme.

[^]
78.

Mellinghoff IK et. al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

[^]
79.

Bao S et. al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

[^]
80.

Pfister S et. al. (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

[^]
81.

Savaskan NE et. al. (2008) Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema.

[^]
82.

Blumenthal DT et. al. (2008) Familiality in brain tumors.

[^]
83.

Zheng H et. al. (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.

[^]
84.

El Hallani S et. al. (2009) TP53 codon 72 polymorphism is associated with age at onset of glioblastoma.

[^]
85.

De Carli E et. al. (2009) IDH1 and IDH2 mutations in gliomas.

[^]
86.

Yu J et. al. (2009) Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma.

[^]
87.

Carro MS et. al. (2010) The transcriptional network for mesenchymal transformation of brain tumours.

[^]
88.

Kyritsis AP et. al. (2010) Inherited predisposition to glioma.

[^]
89.

Labussière M et. al. (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

[^]
90.

Sheng Z et. al. (2010) A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.

[^]
91.

Johnson RA et. al. (2010) Cross-species genomics matches driver mutations and cell compartments to model ependymoma.

[^]
92.

Wang R et. al. (2010) Glioblastoma stem-like cells give rise to tumour endothelium.

[^]
93.

Ricci-Vitiani L et. al. (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.

[^]
94.

Bredel M et. al. (2011) NFKBIA deletion in glioblastomas.

[^]
95.

Bettegowda C et. al. (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma.

[^]
96.

Schwartzentruber J et. al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

[^]
97.

Wu G et. al. (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.

[^]
98.

Muller FL et. al. (2012) Passenger deletions generate therapeutic vulnerabilities in cancer.

[^]
99.

Lewis PW et. al. (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.

[^]
100.

Frattini V et. al. (2013) The integrated landscape of driver genomic alterations in glioblastoma.

[^]
101.

Parker M et. al. (2014) C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.

[^]
102.

Mack SC et. al. (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.

[^]
103.

Funato K et. al. (2014) Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.

[^]
104.

Kim D et. al. (2015) SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance.

[^]
105.

et. al. (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

[^]
106.

Eckel-Passow JE et. al. (2015) Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

[^]
107.

Jahani-Asl A et. al. (2016) Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.

[^]
Update: 26. September 2018

 

Die Seite verwendet Cookies, um Ihnen den bestmöglichen Service zu gewährleisten. Bitte bestätigen Sie uns kurz per Klick, dass Sie mit der Nutzung von Cookies einverstanden sind: